Researchers, Nelius T, Klatte T, de Riese W, Haynes A, Filleur S. from the Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX. studied the efficacy of cyclophosphamide (CP)-based metronomic chemotherapy in men who have docetaxel-resistant hormone-refractory prostate cancer (HRPC). […]
Hot off the press- The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis SA's new chemotherapy drug for advanced prostate cancer. The drug, Jevtana (cabazitaxe) extended by nearly 2-1/2 months the lives of men with prostate cancer tumors that resist standard treatment with hormones as well as chemotherapy. The drug will be used after [...]
The approval of Provenge has once again brought to the forefront the very important questions about the proper timing of treatments as well as the issue concerning how to combine therapies to maximize survival. We have, although there numbers are limited, different treatments that are used for the treatment of advanced prostate cancer, but we [...]
Did you hear the news? These alarming 2010 projections for prostate cancer deaths were just released. Isn't it nice that they were released just prior to Father’s Day, so have a happy Father’s Day. These projections call for a massive 17 % increase in prostate cancer caused deaths as well as a more than 13 [...]
Johns Hopkins, Roswell Park Cancer Institute and Duke University have announced data at the ASCO meeting in Chicago from a 200 man phase II clinical trial of a blood vessel-blocking drug called tasquinimod. This “anti-angiogenesis” drug constricts the blood supply to prostate tumors by blocking new blood vessel development. The study showed that tasquinimod slowed [...]
I received a telephone call recently from a man who was angry and upset. All he could say was, but I’m not dying, I’m not dying! I was finally able to calm him down enough to be able to get him to tell me his story. It seems that his doctor told him that it [...]
As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]
A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]
It is truly amazing and very shocking, from 1996 to 1999, the U.S. food and Drug Administration (FDA) approved 157 new drugs. Compared to the period of 2006 to 2009 the FDA approved 74 drugs. However, NOT one of these approved drugs provided a cure for any serious illness! Diseases that destroy lives, diseases like [...]
In 2007 a Norwegian cancer therapeutics company, Algeta, presented data from a phase II study that showed a remarkable two-year survival advantage with its investigational drug, Alpharadin (radium-223), when used as a as a treatment for castrate resistant prostate cancer (CRPC). […]
